

# Giovanni Rizzo

## List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11972431/giovanni-rizzo-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16

papers

3,305

citations

15

h-index

16

g-index

16

ext. papers

3,639

ext. citations

7.7

avg, IF

4.2

L-index

#	Paper	IF	Citations
16	DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression. <i>Cancer Research</i> , <b>2016</b> , 76, 594-606	10.1	58
15	Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity. <i>Bioorganic and Medicinal Chemistry</i> , <b>2013</b> , 21, 3780-9	3.4	14
14	Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists. <i>Bioorganic and Medicinal Chemistry</i> , <b>2012</b> , 20, 3429-45	3.4	32
13	Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators. <i>ACS Medicinal Chemistry Letters</i> , <b>2012</b> , 3, 273-7	4.3	26
12	TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. <i>Cell Metabolism</i> , <b>2011</b> , 14, 747-57	24.6	364
11	Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamylxy)-3 $\beta$ -dihydroxy-6 $\alpha$ -ethyl-24-nor-5 $\alpha$ -cholan-23-amine. <i>Bioorganic and Medicinal Chemistry</i> , <b>2011</b> , 19, 2650-8	3.4	32
10	Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. <i>Molecular Pharmacology</i> , <b>2010</b> , 78, 617-30	4.3	137
9	TGR5-mediated bile acid sensing controls glucose homeostasis. <i>Cell Metabolism</i> , <b>2009</b> , 10, 167-77	24.6	1184
8	The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. <i>Molecular Pharmacology</i> , <b>2006</b> , 70, 1164-73	4.3	127
7	Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. <i>Journal of Medicinal Chemistry</i> , <b>2006</b> , 49, 4208-15	8.3	41
6	PPARs and other nuclear receptors in inflammation. <i>Current Opinion in Pharmacology</i> , <b>2006</b> , 6, 421-7	5.1	108
5	Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 315, 58-68	4.7	147
4	The third gas: H <sub>2</sub> S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. <i>Hepatology</i> , <b>2005</b> , 42, 539-48	11.2	459
3	A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 314, 584-95	4.7	155
2	The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 551-8	4.3	68
1	The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. <i>Gastroenterology</i> , <b>2004</b> , 127, 1497-512	13.3	353